CIPLA
Back to Income Statement
|
CIPLA Last 5 Year Consolidated Net Profit History
[Consolidated]
| Mar2025 | Mar2024 | Mar2023 | Mar2022 | Mar2021 | |
|---|---|---|---|---|---|
| Consolidated Net Profit | ₹4,122 Cr | ₹2,802 Cr | ₹2,517 Cr | ₹2,405 Cr | ₹1,547 Cr |
What is the latest Consolidated Net Profit of CIPLA ?
| Year | Consolidated Net Profit |
|---|---|
| Mar2025 | ₹4,122 Cr |
| Mar2024 | ₹2,802 Cr |
| Mar2023 | ₹2,517 Cr |
| Mar2022 | ₹2,405 Cr |
| Mar2021 | ₹1,547 Cr |
How is Consolidated Net Profit of CIPLA Trending?
| Years | Consolidated Net Profit | % Change | |
|---|---|---|---|
| Mar2025 | ₹4,122 Cr | 47.10 | |
| Mar2024 | ₹2,802 Cr | 11.33 | |
| Mar2023 | ₹2,517 Cr | 4.65 | |
| Mar2022 | ₹2,405 Cr | 55.50 | |
| Mar2021 | ₹1,547 Cr | - | |
Compare Consolidated Net Profit of peers of CIPLA
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| CIPLA | ₹99,327.1 Cr | 2.4% | -7.2% | -18.1% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹397,018.0 Cr | -2.3% | -8.5% | -3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹162,454.0 Cr | 5.3% | -3.4% | 3.4% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹140,702.0 Cr | 3.7% | -4.9% | 26% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹102,830.0 Cr | 1.2% | -4.2% | 5.3% | Stock Analytics | |
| MANKIND PHARMA | ₹85,816.7 Cr | 3% | -3.9% | -15.4% | Stock Analytics | |
CIPLA Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| CIPLA | 2.4% |
-7.2% |
-18.1% |
| SENSEX | 5.8% |
-1.7% |
1.2% |
You may also like the below Video Courses